The US Court of Appeals for the Fifth Circuit issued a significant decision upholding Louisiana’s Act 358, a state law that prohibits pharmaceutical manufacturers from interfering with covered entities’ use of contract pharmacies under the federal 340B Drug Pricing Program. In a unanimous opinion authored by Judge Don R. Willett, the court rejected industry challenges, asserting federal preemption and constitutional violations, affirming summary judgment in favor of the State of Louisiana. The court explained that “[s]tates regulate pharmacies—and the distribution of drugs to those pharmacies—every day. Act 358 fits comfortably within that tradition.”

This decision reinforces recent appellate authority supporting state efforts to protect covered entities’ access to 340B drugs through contract pharmacy arrangements and has meaningful implications for hospitals and other health care providers operating in the Fifth Circuit and beyond.

Section 340B of the Public Health Service Act requires drug manufacturers participating in Medicaid and the Medicare Part B program to provide outpatient drugs at a discount to “covered entities” that include certain hospitals, clinics and other safety-net providers. Many covered entities do not operate an in-house pharmacy and instead rely on third-party contract pharmacies to dispense 340B drugs to eligible patients.

As the number of contract pharmacies has increased following permissive guidance issued by the Health Resources and Services Administration, manufacturers have sought to limit 340B distribution through contract pharmacies. In 2023, Louisiana enacted Act 358, which prohibits drug manufacturers and distributors from denying, restricting or otherwise interfering with the acquisition or delivery of 340B drugs to pharmacies that contract with covered entities. The law authorizes the Louisiana Attorney General to enforce its provisions and specifies that any violation also constitutes a violation of Louisiana’s Unfair Trade Practices and Consumer Protection Law.

The law was challenged by two manufacturers and a trade association, in separate lawsuits, which were resolved together by the federal District Court for the Western District of Louisiana. The District Court granted summary judgment to the State of Louisiana, and the manufacturers appealed. The Fifth Circuit held that Act 358 is not preempted by federal law because Section 340B regulates pricing and eligibility but not drug delivery logistics and the role of contract pharmacies. The Court reiterated that the 340B “conspicuously does not regulate: ‘neither the distribution of drugs to patients nor the role of pharmacies in this distribution.’” Instead, these fall within states’ traditional authority to regulate public health and pharmacy distribution and that “Act 358 does not regulate the 340B Program itself.” The Court emphasized that Act 358 does not alter manufacturers’ federal pricing obligations and applies once a covered entity has purchased drugs at the 340B price.

The Fifth Circuit rejected the allegation that Act 358 violates the Takings Clause. Citing decisions from the DC Circuit and Third Circuit, the plaintiffs alleged that Act 358 would require drugmakers to provide discounts to unlimited contract pharmacies. The Court found reliance on these decisions to be misplaced because they “held only that HHS lacks authority under 340B to mandate delivery to unlimited contract pharmacies.” Under Act 358, the drug manufacturers continue to be paid at the 340B ceiling price.

The Louisiana law prohibits interference with covered entities’ post-purchase distribution decisions. The court explained that “[m]anufacturers must still offer covered entities the 340B ceiling price, exactly as federal law requires… Act 358 comes into play only after a covered entity has purchased the drugs and directs their delivery to a contract pharmacy.” The Court also rejected the plaintiffs’ allegation that Act 358 violates the Contracts Clause, finding that Act 358 does not rewrite or interfere with the manufacturers’ contracts with the federal government.

Finally, the Court rejected the allegation that the law is unconstitutionally vague. Instead, the Court found that Act 358 targets conduct that obstructs or impedes the delivery of 340B drugs.

The Fifth Circuit’s decision strengthens the ability for state-level 340B legislation and will provide greater certainty for providers that rely on contract pharmacies to serve vulnerable patients. However, this decision does not alleviate the scrutiny and pressure on the 340B program coming from Congress, enforcers and drug manufacturers. Providers should continue to follow developments affecting the 340B program and reevaluate their contract pharmacy arrangements considering evolving laws and enforcement priorities.

Our team of experienced lawyers and professionals at Norton Rose Fulbright monitors updates on the 340B Drug Pricing Program. If you have any questions, please do not hesitate to contact us.

Contact